Literature DB >> 22417649

Synthesis and antiviral activity of 6-deoxycyclopropavir, a new prodrug of cyclopropavir.

Chengwei Li1, Debra C Quenelle, Mark N Prichard, John C Drach, Jiri Zemlicka.   

Abstract

Synthesis of 6-deoxycyclopropavir (10), a prodrug of cyclopropavir (1) and its in vitro and in vivo antiviral activity is described. 2-Amino-6-chloropurine methylenecyclopropane 13 was transformed to its 6-iodo derivative 14 which was reduced to prodrug 10. It is converted to cyclopropavir (1) by the action of xanthine oxidase and this reaction can also occur in vivo. Compound 10 lacked significant in vitro activity against human cytomegalovirus (HCMV), human herpes virus 1 and 2 (HSV-1 and HSV-2), human immunodeficiency virus type 1 (HIV-1), human hepatitis B virus (HBV), Epstein-Barr virus (EBV), vaccinia virus and cowpox virus. In contrast, prodrug 10 given orally was as active as cyclopropavir (1) reported previously [Kern, E. R.; Bidanset, D. J.; Hartline, C. B.; Yan, Z.; Zemlicka, J.; Quenelle, D. C. et al. Antimicrob. Agents Chemother. 2004, 48, 4745] against murine cytomegalovirus (MCMV) infection in mice and against HCMV in severe combined immunodeficient (SCID) mice.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22417649      PMCID: PMC3690936          DOI: 10.1016/j.bmc.2012.02.031

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  15 in total

1.  Efficacy of CMX001 against herpes simplex virus infections in mice and correlations with drug distribution studies.

Authors:  Debra C Quenelle; Bernhardt Lampert; Deborah J Collins; Terri L Rice; George R Painter; Earl R Kern
Journal:  J Infect Dis       Date:  2010-10-05       Impact factor: 5.226

2.  A515U: a prodrug of acyclovir with increased oral bioavailability.

Authors:  P J Rees; P Selby; H G Prentice; P D Whiteman; D M Grant
Journal:  J Antimicrob Chemother       Date:  1986-10       Impact factor: 5.790

3.  Alkoxyalkyl esters of cidofovir and cyclic cidofovir exhibit multiple-log enhancement of antiviral activity against cytomegalovirus and herpesvirus replication in vitro.

Authors:  James R Beadle; Caroll Hartline; Kathy A Aldern; Natalie Rodriguez; Emma Harden; Earl R Kern; Karl Y Hostetler
Journal:  Antimicrob Agents Chemother       Date:  2002-08       Impact factor: 5.191

4.  Oral activity of ether lipid ester prodrugs of cidofovir against experimental human cytomegalovirus infection.

Authors:  Deborah J Bidanset; James R Beadle; W Brad Wan; Karl Y Hostetler; Earl R Kern
Journal:  J Infect Dis       Date:  2004-07-01       Impact factor: 5.226

5.  Aldehyde oxidase from rabbit liver: specificity toward purines and their analogs.

Authors:  W W Hall; T A Krenitsky
Journal:  Arch Biochem Biophys       Date:  1986-11-15       Impact factor: 4.013

6.  Synthesis and antiviral activity of (Z)- and (E)-2,2-[bis(hydroxymethyl)cyclopropylidene]methylpurines and -pyrimidines: second-generation methylenecyclopropane analogues of nucleosides.

Authors:  Shaoman Zhou; Julie M Breitenbach; Katherine Z Borysko; John C Drach; Earl R Kern; Elizabeth Gullen; Yung-Chi Cheng; Jiri Zemlicka
Journal:  J Med Chem       Date:  2004-01-29       Impact factor: 7.446

7.  6-Deoxyacyclovir: a xanthine oxidase-activated prodrug of acyclovir.

Authors:  T A Krenitsky; W W Hall; P de Miranda; L M Beauchamp; H J Schaeffer; P D Whiteman
Journal:  Proc Natl Acad Sci U S A       Date:  1984-05       Impact factor: 11.205

8.  Synthesis and biological activity of 2-aminopurine methylenecyclopropane analogues of nucleosides.

Authors:  Ruifang Wang; Xinchao Chen; John C Drach; Earl R Kern; Jiri Zemlicka
Journal:  Nucleosides Nucleotides Nucleic Acids       Date:  2003-02       Impact factor: 1.381

9.  Prodrugs of the selective antiherpesvirus agent 9-[4-hydroxy-3-(hydroxymethyl)but-1-yl]guanine (BRL 39123) with improved gastrointestinal absorption properties.

Authors:  M R Harnden; R L Jarvest; M R Boyd; D Sutton; R A Vere Hodge
Journal:  J Med Chem       Date:  1989-08       Impact factor: 7.446

10.  Metabolism and pharmacokinetics of a double prodrug of ganciclovir in the rat and monkey.

Authors:  H C Krasny; L Beauchamp; T A Krenitsky; P de Miranda
Journal:  Drug Metab Dispos       Date:  1995-11       Impact factor: 3.922

View more
  2 in total

Review 1.  KSHV targeted therapy: an update on inhibitors of viral lytic replication.

Authors:  Natacha Coen; Sophie Duraffour; Robert Snoeck; Graciela Andrei
Journal:  Viruses       Date:  2014-11-24       Impact factor: 5.048

Review 2.  Contribution of the KSHV and EBV lytic cycles to tumourigenesis.

Authors:  Oliver Manners; James C Murphy; Alex Coleman; David J Hughes; Adrian Whitehouse
Journal:  Curr Opin Virol       Date:  2018-09-28       Impact factor: 7.090

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.